Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Microbial Asymmetric Reduction. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN1254760A reveals microbial route for Actinol. Enhances supply chain reliability and cost reduction in carotenoid intermediate manufacturing significantly.
Patent CN100376681C details a microbial asymmetric reduction method for (R)-mandelic acid using Saccharomyces cerevisiae, offering a green, cost-effective alternative to traditional chemical resolution for pharmaceutical manufacturing.
Patent CN102199633B reveals a green yeast-based route for high-purity chiral esters, offering significant cost and supply chain advantages for pharma.
Patent CN102643879B reveals microbial route for duloxetine intermediate. High purity, scalable production offers significant supply chain and cost advantages.
Patent CN103589665A reveals a novel Rhodococcus qingshengii strain for high-purity (S)-CHBE production, offering significant cost reduction in API manufacturing.
Patent CN103589665B reveals Rhodococcus qingshengii strain for high-purity (S)-CHBE production. Offers mild conditions and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN101824438A reveals microbial conversion for high-purity chiral intermediates. Offers cost reduction and scalable supply chain solutions for pharmaceutical manufacturing partners globally.